Roivant Sciences (ROIV) Total Current Liabilities (2021 - 2026)

Roivant Sciences has reported Total Current Liabilities for 6 years, with the latest figure at $281.2 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities rose 88.24% year-over-year to $281.2 million; the trailing twelve-month figure through Mar 2026 stood at $281.2 million (up 88.24% YoY), and the FY2026 full-year result was $281.2 million, up 88.24% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $281.2 million, down from $469.1 million in the prior quarter.
• The five-year high for Total Current Liabilities was $556.2 million in Q3 2024, with the low at $113.9 million in Q2 2025.
• Historically, Total Current Liabilities has averaged $270.4 million across 5 years, with a median of $265.5 million in 2023.
• Annual changes were most pronounced in 2024 — Total Current Liabilities surged 109.47% — and 2025, when it sank 75.94%.
• Roivant Sciences' Total Current Liabilities stood at $244.3 million in 2022, then grew by 27.36% to $311.1 million in 2023, then rose by 5.96% to $329.6 million in 2024, then surged by 42.3% to $469.1 million in 2025, then slumped by 40.04% to $281.2 million in 2026.
• The last three Total Current Liabilities figures came in at $281.2 million (Q1 2026), $469.1 million (Q4 2025), and $133.9 million (Q3 2025), per Business Quant data.